Sign inJoin waitlistJoin the waitlist

Hamid Mirshahidi

Chief, Medical Oncology-Hematology · Loma Linda University Health Education Consortium

Credentials: · · · ·

History

Medical Oncology-Hematology Division · Loma Linda University Health Education Consortium
Present
Medical Oncology Department · Loma Linda University Health Education Consortium
Present
Loma Linda University Health Education Consortium
Present

Hematology and Medical Oncology
West Virginia University School of Medicine
1995–1998
Trinity Health
1992–1995
Doctor of Medicine
1988–1992

Research

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare…
Clinical Cancer Research · 2022 · 120 citations
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Review · Journal of Hematology & Oncology · 2011 · Last of 4 authors · Corresponding · 98 citations
High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at…
International journal of radiation oncology · 2013 · 81 citations

Mark Reeves
7 papers
Huynh Cao
6 papers · 1 as a fellow
Anthony Nguyen
5 papers · 5 as a fellow
Lee Zuckerman
5 papers
DB
David Baylink
4 papers
Laren Tan
4 papers
NW
Nadine Williams
4 papers
Salman Otoukesh
4 papers · 4 as a fellow
Chien-Shing Chen
3 papers
Chung Hsueh
3 papers
Danielle Castillo
3 papers · 3 as a fellow
David Bush
3 papers

Clinical trials

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2028